Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy
Pharmaceutical Research (2021)
Institution: Northeastern University, USA
Cell Line: MDA-MD-231 (Human mammary carcinoma cell line)
Research Area: Drug activity
Conclusions: Improving the various properties, such as biodistribution and solubility, are the main driving force for using nano-carries in drug deliveries. In this study, the authors have used monoclonal antibody modified immunoliposomes for targeted delivery of paclitaxel and salinomycin for cancer therapy. Researchers have shown that a combination of drugs increases therapeutical efficacy when delivered in immunoliposomes. HoloMonitor M4 was used to study cell killing, cell division and proliferation post-treatment.